Kukje Pharma Co., Ltd. (KRX:002720)
3,435.00
+50.00 (1.48%)
Sep 1, 2026, 3:30 PM KST
Kukje Pharma Revenue
Kukje Pharma had revenue of 48.32B KRW in the quarter ending June 30, 2026, with 7.32% growth. This brings the company's revenue in the last twelve months to 181.27B, up 8.02% year-over-year. In the year 2025, Kukje Pharma had annual revenue of 175.50B with 12.16% growth.
Revenue (ttm)
181.27B
Revenue Growth
+8.02%
P/S Ratio
0.38
Revenue / Employee
730.91M
Employees
248
Market Cap
68.93B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 175.50B | 19.03B | 12.16% |
| Dec 31, 2024 | 156.46B | 21.09B | 15.58% |
| Dec 31, 2023 | 135.37B | 8.79B | 6.94% |
| Dec 31, 2022 | 126.58B | 6.84B | 5.71% |
| Dec 31, 2021 | 119.75B | -10.65B | -8.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 630.89B |
| Ildong Holdings | 607.65B |
| HANDOK | 560.89B |
| HLB Pharmaceutical | 251.95B |
| MYUNGMOON Pharm co.,Ltd | 199.82B |
| CKD Bio | 159.93B |
| Yuyu Pharma | 144.37B |
| CMG Pharmaceutical | 115.71B |